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Background: Capreomycin is a key antimycobacterial drug in
treatment of extensively drug-resistant tuberculosis (XDR-TB).
Drug-susceptibility testing (DST) for capreomycin is not routinely
performed in newly diagnosed XDR-TB in South Africa. We
performed this study to assess the prevalence, clinical significance,
and molecular epidemiology of capreomycin resistance in newly
diagnosed patients with XDR-TB in KwaZulu-Natal, South Africa.
Methods: Retrospective cohort study of consecutive patients with
XDR-TB admitted to a TB referral hospital without previous XDR-
TB treatment. A subset of isolates had extended DST (including
capreomycin), mutational analysis, and IS6110 restriction fragment
length polymorphism assays.
Results: A total of 216 eligible patients with XDR-TB were
identified. The majority were treated with capreomycin (72%), were
young (median age: 35.5 years), and were female (56%). One
hundred five (76%) were HIV+, and 109 (66%) were on antire-
troviral therapy. A subset of 52 patients had full DST. A total of
47/52 (90.4%) patients with XDR-TB were capreomycin resistant.
Capreomycin-resistant patients experienced worse mortality and
culture conversion than capreomycin susceptible, although this
difference was not statistically significant. The A1401G mutation
in the rrs gene was associated with capreomycin resistance. The
majority of capreomycin-resistant strains were F15/LAM4/KZN
lineage (80%), and clustering was common in these isolates (92.5%).
Conclusions: Capreomycin resistance is common in patients with
XDR-TB in KwaZulu-Natal, is predominantly because of ongoing
province-wide transmission of a highly resistant strain, and is
associated with high mortality. Capreomycin should be included in
routine DST in all patients with XDR-TB. New drug regimens that
do not include injectable agents should be operationally tested as
empiric treatment in XDR-TB.
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INTRODUCTION
Drug-resistant tuberculosis exacerbated by endemic
HIV has been well described in KwaZulu-Natal, South
Africa.1–5 Extensively drug-resistant tuberculosis (XDR-TB)
is the most drug-resistant form of TB and is defined as
Mycobacterium tuberculosis (MTB) resistant to isoniazid,
rifampicin, any fluoroquinolone drug, and at least one of the 3
second-line injectable agents (kanamycin, amikacin, and
capreomycin).6 A hospital-based outbreak of XDR-TB and
HIV in Tugela Ferry, KwaZulu-Natal, in 2005 attracted
significant global attention to this syndemic.7
A key component of the current XDR-TB treatment
regimen is capreomycin, an injectable antimycobacterial
agent in the cyclic peptide class. Globally, capreomycin is
included in XDR-TB treatment regimens for its excellent
bactericidal activity and lack of availability of alternative
bactericidal agents for densely drug-resistant MTB. Since
2006, in KwaZulu-Natal, South Africa, capreomycin has been
available and is restricted for treatment of XDR-TB. Cross-
resistance between aminoglycosides and capreomycin asso-
ciated with polymorphisms within rrs gene has been
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described, but the population-level prevalence of capreomy-
cin resistance is unknown.8,9
Drug-susceptibility testing (DST) is an essential aspect of
the management of drug-resistant TB. However, full DST to
second-line antimycobacterial agents is not routinely performed
globally even in patients with known multidrug-resistant
tuberculosis (MDR-TB).10 Until recently, capreomycin DST
was not routinely performed in KwaZulu-Natal outside the
research setting because of resource constraints. Current World
Health Organization guidelines on treatment of XDR-TB
recommend that in the setting of resistance to aminoglycosides
to use an injectable agent, which the patient has not used before
since clinical data on the efficacy of DST is limited.
We performed this study to determine the prevalence of
capreomycin resistance in patients with XDR-TB before
treatment with capreomycin-containing TB regimens in
KwaZulu-Natal, South Africa, to elucidate the mechanism of
capreomycin drug resistance and understand the clinical impli-
cations of capreomycin resistance for patients with XDR-TB.
METHODS
Clinical
We performed a retrospective cohort study of all newly
diagnosed, microbiologically confirmed, adult patients with
XDR-TB admitted from January 2008 to September 2010 in
a public TB referral hospital in KZN. Eligible patients were
adults with microbiologically confirmed XDR-TB by DST
without previous therapy for XDR-TB. Demographics
and clinical data were collected by retrospective chart
review. TB culture results and routine first- and second-line
TABLE 1. Demographic Characteristics of Eligible Patients With XDR-TB Admitted to King DinuZulu Hospital During the Study
Period (N = 216) and the Subset With Extended DST and Genotyping (N = 52)
All Patients With XDR-TB,
N = 216 (%)
Patients With XDR-TB With
Isolates for DST and Genotyping,
N = 52 (%)
Patients With XDR-TB Without
Isolates for DST and Genotyping,
N = 164 (%)
P Patients With DST
vs. No DST
Sex
Male 95 (44) 26 (50) 69 (42) 0.32
Female 121 (56) 26 (50) 95 (58)
Age, yrs
#35 108 (50) 24 (46) 84 (51) 0.52
.35 108 (50) 28 (54) 80 (49)
Median age 35.5 36.5
Body mass index
Obtained 99 (46) 25 (48) 74 (45) 0.71
Not obtained 117 (54) 27 (52) 90 (55)
Median (IQR) 19 (16–23) 18 (16–23)
HIV status
Infected 165 (77) 44 (84) 121 (74) 0.19
Uninfected 32 (14) 5 (10) 27 (16)
Unknown 19 (8) 3 (6) 16 (10)
CD4 T-cell* count,
cells/mm3
Known 93 (56) 25 (57) 68 (56) 0.40
Not determined 72 (44) 19 (43) 53 (44)
Median (IQR) 195 (105–302) 192 (112–234)
ARV*
Yes 114 (69) 31 (70) 83 (69) 0.82
No 51 (31) 13 (30) 38 (31)
Previous TB
treatment
Yes 207 (96) 51 (98) 156 (95) 0.37
No 9 (4) 1 (2) 8 (5)
Initial AFB smear
Positive 108 (50) 30 (58) 78 (47) 0.38
Negative 98 (45) 22 (42) 76 (46)
Unknown 10 (5) 0 10 (6)
Health care worker
Yes 16 (7) 3 (6) 13 (8) 0.61
No 200 (93) 49 (94) 151 (92)
*Among HIV infected.
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drug-susceptibility results were collected retrospectively
through the clinical laboratory system. Treatment regimen
was determined by the attending physician. The standard of
treatment for XDR-TB was individualized therapy according
to DST and patient tolerance. TB sputum culture conversion
was defined as having .2 negative consecutive sputum
cultures 30 days apart after initiation of treatment. Mortality
was defined as all-cause mortality.
All eligible patients in the study were included in an
analysis of risk factors for survival and culture conversion.
Proportional hazards regression analysis was performed to
assess factors associated with death and culture conversion.
Cox proportional hazards were used to estimate hazard ratios
(HRs) and 95% confidence intervals (CIs) at 6 months after
initiation of XDR-TB treatment. Significant variables or
variables that caused .10% change in the univariate HR were
included in the multivariate model. We calculated 95% CIs
using a normal approximation of the binomial distribution. The
Fisher exact test or x2 test was used to compare categorical
variables. Kaplan–Meier survival curves for death and for time
to culture conversion were calculated using standard techni-
ques from time of XDR-TB treatment initiation with appro-
priate anti-TB drugs. Time to culture conversion and mortality
were censored at 6 months because long-term follow-up data
are not available. Statistical analysis was performed using SAS
version 9.2 software (SAS Institute, Cary, NC).
Microbiology
MTB isolates were sought for all patients from a time
before initiation of XDR-TB treatment. If isolates before
treatment were not available, we included isolates up to 3
months after initiation of treatment. These isolates were
subcultured from stocks from the regional TB laboratory. Full
DST including capreomycin testing was performed using the
1% proportional method on Middlebrook 7H11 agar using
standard antibiotic concentrations (10 mg/mL cut point).
Extended DST to determine moxifloxacin minimum inhibitory
concentration (MIC) using clinically relevant cut points (0.125,
0.25, 0.5, 1, 2, 4, and 8 mg/mL) was also performed.11,12
A commercial kit (Geno Type MTBDRsl; Hain Lifescience,
GmbH, Neheren, Germany) was used to probe for known
resistance conferring mutations in the rrs gene.
Genotyping
Single MTB isolates of patients with capreomycin-
resistant XDR-TB were genotyped by performing IS6110
restriction fragment length polymorphism (RFLP).13,14
Briefly, cetyltrimethylammonium bromide (CTAB)-
extracted genomic DNA was restricted with the restriction
endonuclease PvuII, separated in a 1% agarose gel and
immobilized onto a Hybond-N+ nylon membrane
(Amersham). IS6110-fragments were hybridized and de-
tected using enhanced chemiluminescence (Amersham).
Banding patterns were analyzed with BioNumerics ver-
sion 6.6 (Applied Maths). Isolates were considered clus-
tered if they had greater than 3 bands identical without
discordant bands.
Ethics approval was obtained through the Boston
University Medical Center Institutional Review Board and
the Biomedical Research Ethics Committee of the Univer-
sity of KwaZulu-Natal.
RESULTS
We identified 216 adult patients during the study period
with bacteriologically confirmed TB, DST consistent with
XDR-TB, who had not undergone previous treatment for
XDR-TB (Table 1). Patients were predominantly female
(56%), with a median age of 35.5 years, and TB treatment
experienced (96% previously treated for TB). Eighty-four
percent (165/197) of patients with a known HIV status were
HIV coinfected. Forty-five percent of all patients (98/216)
were acid-fast bacilli (AFB) smear negative at treatment start.
The majority of HIV-coinfected patients with XDR-TB (65%)
were on antiretroviral therapy, and median CD4 T-cell count
was 195 [interquartile range (IQR), 105–302] at commence-
ment of XDR-TB treatment. Patients were tested for resis-
tance to 6 drugs (kanamycin, ofloxacin, isoniazid, rifampicin,
streptomycin, and ethambutol) and on average were resistant
to 5.7 drugs. Capreomycin-susceptibility testing was not
FIGURE 1. Initial XDR-TB treatment
regimen for patients with XDR-TB on
treatment (N = 216).
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performed on these isolates, as it was not clinically available
during the study period. Patients were started on XDR-TB
treatment regimens that included a median of 5 drugs (Fig. 1).
Capreomycin (72%) and para-aminosalicylic acid (73%) were
components of the XDR-TB treatment regimen for most of
the patients. Treatment strategy was determined by the
resident physician, and 60/216 (28%) did not receive
capreomycin. Among those who did not receive capreomycin
as part of their regimen, 25/60 received an aminoglycoside
and 25/60 received an alternative fluoroquinolone (moxiflox-
acin or ofloxacin).
During the first 6 months of treatment, 49/216 (22.7%)
patients died and 21.6% converted their sputum TB culture to
negative. On multivariate analysis, the presence of moxiflox-
acin in the initial treatment regimen was associated with
improved survival [HR, 0.13 (95% CI: 0.031 to 0.54)] in the
first 6 months of treatment (Table 2). Older age was
significantly associated with increased mortality [HR, 1.18
(95% CI: 1.02 to 1.37) per every 5 years of increased age].
There were no factors independently associated with 6-month
culture conversion (data not shown).
Fifty-two XDR-TB isolates (52/216, 24%) were iden-
tified and found to be viable for further testing. MIC testing
for capreomycin was performed using agar dilution method
on 52 clinical isolates. Forty-seven (90%) patients with XDR-
TB were capreomycin resistant. A total of 37/52 specimens
were collected before initiation of XDR-TB treatment. Of the
37 samples collected before XDR treatment, 94% were
capreomycin resistant. Of the 15 samples collected after
initiation of XDR-TB treatment, 80% were capreomycin
resistant. This difference was not statistically significant
(P = 0.13). Samples collected after XDR treatment were
collected mean 72 days after initiation (SD 45.5 days). Of
note, 4/52 patients had been treated for MDR-TB with
aminoglycosides previously. The Geno Type MTBDRsl
assay codons 1401, 1402, and 1484 of the rrs gene were
analyzed. Mutations tested for included A1401G, C1402T,
and G1484T. Forty-seven (100%) of the capreomycin-
resistant isolates harbored the rrs A1401G mutation. None
of the 5 capreomycin-susceptible isolates had this mutation.
Neither C1402T nor G1484T mutations were detected in
any isolate. Despite the fact that all XDR-TB isolates were
resistant to ofloxacin, 47% had MICs of less than 2 mg/mL
for moxifloxacin (the proposed “high” critical concentra-
tion for moxifoxacin drug susceptibility) and 27% had
MICs of 0.50 mg/mL or less (the proposed “low” critical
value) (see Figure S1, Supplemental Digital Content, http://
links.lww.com/QAI/A672).
Patients with capreomycin-resistant isolates (N = 47)
had lower rates of 6-month TB culture conversion (25% vs.
60%) and higher mortality (20% vs. 0%) compared with
patients with capreomycin-susceptible isolates, but this
difference was not statistically significant (P = 0.35 and P =
0.0573, respectively) (Figs. 2A, B).
Of the 47 capreomycin-resistant isolates, 44 (83%) were
successfully genotyped using RFLP; no RFLP fingerprint
patterns were obtained for 4 isolates despite DNA being present.
Five different strain types were identified among the remaining
40 isolates (see Table S1, Supplemental Digital Content, http://
links.lww.com/QAI/A672). The F15/LAM4/KZN genotype,
which was identified in 35/40 (87.5%) patients, could be
divided into 4 subclusters separated by copy number of a few
IS6110 elements. None of the patients was infected with
a Beijing strain.
TABLE 2. Risk Factors for Mortality Among Patients With XDR-TB on Treatment 6 Months After Initiation of Treatment
Variable Mortality, % (n/N)
Univariate Analysis Multivariate Analysis
HR (95% CI) P HR (95% CI) P
Capreomycin
No 18.3 (11/60) 1.00 (ref) — 1.00 (ref) —
Yes 24.4 (38/156) 1.39 (0.71 to 2.72) 0.3387 1.68 (0.83 to 3.41) 0.1486
Moxifloxacin
Yes 4.1 (2/49) 0.127 (0.032 to 0.54) 0.0049 0.13 (0.031 to 0.54) 0.0051
No 28.1 (47/167) 1.00 (ref) — 1.00 (ref) —
Gender
Male 16.8 (16/95) 1.00 (ref) — 1.00 (ref) —
Female 27.3 (33/121) 1.70 (0.94 to 3.09) 0.0806 1.83 (0.96 to 3.49) 0.0675
Age (by 5-yr increase) 1.12 (0.97 to 1.29) 0.1153 1.18 (1.02 to 1.37) 0.0310
Previously treated for TB
Yes 22.2 (46/207) 1.00 (ref) — 1.00 (ref) —
No 28.6 (2/7) 1.25 (0.30 to 5.14) 0.7589 0.97 (0.23 to 4.03) 0.9629
HIV status
Negative 15.6 (5/32) 1.00 (ref) — 1.00 (ref) —
Positive 23.6 (39/165) 1.55 (0.61 to 3.94) 0.3535 1.85 (0.65 to 5.26) 0.2471
Unknown 26.3 (5/19) 1.73 (0.50 to 5.97) 0.3877 3.63 (0.94 to 14.09) 0.0623
ARV (HIV+ only)
Yes 22.0 (24/109) 1.00 (ref) —
No 26.8 (15/56) 1.23 (0.65 to 2.35) 0.5264
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XDR-TB cases were mapped according to the home
address of each patient. The initial reported XDR-TB out-
break was considered to be a point source outbreak in the
Msinga subhealth district (Tugela Ferry). However, in our
cohort, patients reported home address in all 11 provincial
health districts. In terms of RFLP genotyping, the F15/
LAM4/KZN genotype was predominant and widespread
(Figs. 3A, B).
CONCLUSIONS
Our study highlights several important findings. A high
percentage (90%) of newly diagnosed patients with XDR-TB
in KwaZulu-Natal were found to have primary capreomycin
resistance (ie, MTB isolates resistant to capreomycin, either
before, or soon after first exposure to a capreomycin-
containing regimen). Capreomycin resistance was widespread
with cases in all 11 provincial health districts. All
capreomycin-resistant isolates characterized in this cohort
had the same A1401G mutation in rrs gene, a mutation
known to confer capreomycin resistance (and cross-resistance
to aminoglycosides), whereas no susceptible MTB isolates
had this mutation. Capreomycin-resistant XDR-TB isolates
were predominantly (80%) of the same MTB lineage
(F15/LAM4/KZN genotype).15 Although most of the
samples were in clusters (92.5%) by RFLP, there did not
seem to be clustering at the patient’s home locations,
unlike the original Tugela Ferry outbreak.7 Although the
FIGURE 2. A, Kaplan–Meier mortal-
ity among patients with XDR-TB
with full DST (N = 52) stratified by
capreomycin resistance. B, Kaplan–
Meier time to culture conversion
among patients with XDR-TB with
full DST (N = 52) stratified.
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majority were previously treated for TB (92%), few (8%)
had documented previous treatment with aminoglycosides,
making acquired capreomycin resistance in the setting of
cross-resistance with aminoglycosides unlikely. Taken
together, these data suggest that capreomycin resistance
is predominantly because of primary transmission of
a highly drug-resistant strain of MTB in KwaZulu-
Natal.15–18 This hypothesis needs further confirmation in
a population-based study of drug-resistant TB using
whole-genome sequencing.
FIGURE 3. Geographic distribution
of the origin of XDR-TB cases in
KwaZulu-Natal, South Africa. A, Dis-
tribution of all XDR-TB cases by home
address (N = 210). B, Distribution of
capreomycin-resistant XDR-TB cases
by home address (N = 47).
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Predictably, patients with capreomycin-resistant
XDR-TB experienced poor treatment outcomes with lower
rates of TB culture conversion and higher mortality than
patients with capreomycin-susceptible strains through 6
months. On multivariate analysis, moxifloxacin was asso-
ciated with improved early mortality. When we tested
a subset of the MTB isolates for susceptibility to moxi-
floxacin, 27% were moxifloxacin susceptible (based on
World Health Organization recommended critical concen-
tration) despite being resistant to ofloxacin in standard
testing.12 This suggests that the mortality benefit seen with
moxifloxacin treatment in this cohort may be due to partial
or complete susceptibility to moxifloxacin in a subset of
patients with XDR-TB in the context of near-universal
capreomycin resistance.
A recent study of patients with XDR-TB in the Tugela
Ferry area identified a high proportion of capreomycin
resistance (89.5%), but only 19 isolates were tested and
treatment outcomes were not reported.18 All patients were
capreomycin resistant before treatment with either an
amikacin or capreomycin suggesting primary transmission
of a capreomycin-resistant strain. Our study demonstrates that
this phenomenon is considerably more widespread than
previously believed. A European study identified capreomy-
cin resistance as an independent risk factor for poor outcome
in MDR-TB patients, but it was not clear how patients were
treated, whether resistance was primary or secondary, or the
molecular mechanism of resistance.19
One study of XDR-TB treatment in South Africa
identified moxifloxacin as significantly associated with
survival in the first 12 months of treatment20; however, this
survival benefit was not seen with prolonged follow-up.6
Moxifloxacin has been recommended by experts for treatment
of XDR-TB despite flouroquinolone resistance,21 and a meta-
analysis of XDR-TB treatment supported the inclusion of later
generation flouroquinolones in XDR-TB treatment.22 Labo-
ratory studies have been inconclusive regarding the degree
of cross-resistance between early and later generation
fluoroquinolones, although mouse studies support the use
of moxifloxacin in the treatment of XDR-TB. The clinical
benefit of later generation fluoroquinolones in isolates,
which are resistant to earlier generation quinolones, is
poorly characterized.23
Our study has several limitations to generalizability
including having only a subset of isolates for extended DST
and molecular testing. We attempted to retrieve all available
MTB isolates from an operational provincial TB laboratory,
but only 24% were located and culturable. Another limitation
is that the small number of patients with capreomycin-
susceptible XDR-TB (N = 5) means that we have insufficient
power to show a difference between the groups. Since
complete genomic sequencing was not performed, it is
possible that the rrs mutation reported was not the only
contributor to capreomycin resistance. It is possible that with
whole-genome sequencing, we could further discriminate the
genotypic clustering seen on RFLP, or that with a larger
sample other patterns of RFLP clustering would emerge.
Finally, because we did not have access to long-term
follow-up data, the 6-month outcome results obtained may
not reflect treatment outcomes at 24 months, or end of
treatment relapse free survival.
In conclusion, primary capreomycin-resistant XDR-TB in
KwaZulu-Natal, South Africa, is common, geographically
widespread, associated with RFLP clustering, is predominantly
of a single MTB lineage, and seems to be associated with poor
6-month culture conversion and survival. Full first- and second-
line DST, including capreomycin susceptibility, should be
included in routine DST of all patients with XDR-TB. New
drug regimens, which do not depend on capreomycin, should be
operationally tested urgently as empiric treatment in XDR-TB.
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